Neuroimmunology Drug Development (NIDD)
Summary Neuroimmunology is expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimers disease (AD) and Multiple Sclerosis (MS). This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology. Clinical trials analyze ongoing trials by different phases of development and by sponsor type, as well as trends in combination therapy...